M

MGI Tech Co Ltd
SSE:688114

Watchlist Manager
MGI Tech Co Ltd
SSE:688114
Watchlist
Price: 51.7 CNY -0.58% Market Closed
Market Cap: 21.5B CNY
Have any thoughts about
MGI Tech Co Ltd?
Write Note

Operating Margin
MGI Tech Co Ltd

-35.4%
Current
-13%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-35.4%
=
Operating Profit
-912.8m
/
Revenue
2.6B

Operating Margin Across Competitors

Country CN
Market Cap 21.3B CNY
Operating Margin
-35%
Country US
Market Cap 1.2T USD
Operating Margin
14%
Country US
Market Cap 202.3B USD
Operating Margin
17%
Country US
Market Cap 166.6B USD
Operating Margin
21%
Country KR
Market Cap 66.8T KRW
Operating Margin
31%
Country CH
Market Cap 38.4B CHF
Operating Margin
13%
Country US
Market Cap 38.8B USD
Operating Margin
24%
Country US
Market Cap 36.2B USD
Operating Margin
14%
Country US
Market Cap 27B USD
Operating Margin
28%
Country US
Market Cap 24B USD
Operating Margin
20%
Country CN
Market Cap 164.4B CNY
Operating Margin
27%
No Stocks Found

MGI Tech Co Ltd
Glance View

Market Cap
21.3B CNY
Industry
Life Sciences Tools & Services

MGI Tech Co Ltd, a key player in the genomics industry, emerged from the bustling biotech hub of Shenzhen, China, and swiftly carved a niche for itself with cutting-edge sequencing technology. Founded in 2016 as a subsidiary of BGI Group, MGI has dedicated itself to developing advanced genetic sequencing platforms and related products. The company’s mission is clear: to empower life science research and healthcare by providing innovative tools that make sequencing faster, cheaper, and more accessible. At the core of MGI’s success is their proprietary platform sequencing technology, known as the DNBSEQ™, which has garnered attention for its high throughput and accuracy. This technology is pivotal to their business model, as it significantly reduces the cost of sequencing, giving MGI a competitive edge in the market. MGI's business thrives on a dual revenue stream, primarily from the sale of their state-of-the-art sequencing devices and from providing sequencing services. Their portfolio of sequencing platforms, ranging from benchtop sequencers like the MGISEQ-2000 to large-scale units, caters to a diverse clientele, including research institutions, healthcare providers, and industry giants. The company supports this with a robust after-sales service and supply of consumables required for continuous operation, such as reagents and sequencing kits. By embedding itself deeply into the operational frameworks of its clients, MGI not only boosts its device sales but also ensures a persistent revenue flow from ongoing service and supplies. This business model positions MGI Tech Co Ltd as a formidable force, continually driving advancements in genome technology while expanding its global footprint.

Intrinsic Value
39.36 CNY
Overvaluation 24%
Intrinsic Value
Price
M

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-35.4%
=
Operating Profit
-912.8m
/
Revenue
2.6B
What is the Operating Margin of MGI Tech Co Ltd?

Based on MGI Tech Co Ltd's most recent financial statements, the company has Operating Margin of -35.4%.